Hexarelin has limited human research on growth-hormone release and sleep/endocrine effects. There is not strong clinical evidence for the body-composition, recovery or anti-ageing claims often discussed online.
Still uncertain: Body-composition, recovery, performance, sleep or longevity benefit.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Synthetic GH-secretagogue hexapeptide
Entity type
Peptide
Research focus
GH-axis and neuroendocrine research
Human evidence
Small human dose-response studies show GH release plus prolactin/cortisol effects; an overnight study reported reduced selected slow-wave/stage-4 sleep measures despite endocrine stimulation.
Regulatory status
No FDA/EMA-approved hexarelin medicine identified.
Main limitations
Body-composition, recovery, performance, sleep or longevity benefit.
Safety
Endocrine spillover includes prolactin, ACTH and cortisol effects; long-term safety is not established.
Evidence reviewed
2026-09-18
i
Small human dose-response studies show GH release plus prolactin/cortisol effects; an overnight study reported reduced selected slow-wave/stage-4 sleep measures despite endocrine stimulation.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Hexarelin-induced GH, cortisol and prolactin release: dose-response study
1996 · Dose-response human physiology study · n=Small study
Hexarelin produced dose-dependent GH and prolactin responses and a cortisol increase at higher doses; low-dose hexarelin was synergistic with GHRH for GH release.
Endocrine spillover includes prolactin, ACTH and cortisol effects; long-term safety is not established.
Repeated endocrine stimulation may affect other pituitary hormones; long-term lifestyle-use safety is not established.
Technical details
Mechanism / biologyGHS receptor agonist producing strong GH release and also effects on prolactin/ACTH/cortisol.
Route / formulation boundaryAcute GH release is a pharmacodynamic finding, not proof of body-composition or anti-ageing benefit.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human dose-response regimens. Open descriptive regimen evidence →
Identifiers & alternate namesExamorelin · Hex
Source depth & provenance
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
5linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
